Trial · NCT03104699
Results by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 57
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | Phase 1: Balstilimab Dose 1 | 0 | Participants | ||
| Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | Phase 1: Balstilimab Dose 2 | 0 | Participants | ||
| Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | Phase 1: Balstilimab Dose 3 | 0 | Participants | ||
| Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | Phase 1: Balstilimab Dose 4 | 0 | Participants | ||
| Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab | Phase 1: Balstilimab Dose 5 | 0 | Participants | ||
| Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1: Balstilimab Dose 1 | 10 | Participants | ||
| Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1: Balstilimab Dose 2 | 10 | Participants | ||
| Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1: Balstilimab Dose 3 | 10 | Participants | ||
| Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1: Balstilimab Dose 4 | 10 | Participants | ||
| Phase 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | Phase 1: Balstilimab Dose 5 | 10 | Participants | ||
| Phase 2: Objective Response Rate (ORR) as Determined by an Independent Endpoint Review Committee (IERC) | Phase 2: Balstilimab Recommended Phase 2 Dose | 15.6 | 95% Confidence Interval 10.8 to 22.0 | percentage of participants | |
| Phase 1: Receptor Occupancy of Circulating T Cells | Phase 1: Balstilimab Dose 1 | Cycle 1 Day 1 | 73.2 | Standard Deviation 11.95 | percent occupancy |
| Phase 1: Receptor Occupancy of Circulating T Cells | Phase 1: Balstilimab Dose 2 | Cycle 1 Day 1 | 69.4 | Standard Deviation 5.52 | percent occupancy |
| Phase 1: Receptor Occupancy of Circulating T Cells | Phase 1: Balstilimab Dose 4 | Cycle 1 Day 1 | 76.6 | Standard Deviation 2.95 | percent occupancy |
| Phase 1: Receptor Occupancy of Circulating T Cells | Phase 1: Balstilimab Dose 1 | Cycle 2 Day 1 | 67.7 | Standard Deviation 16.93 | percent occupancy |
| Phase 1: Receptor Occupancy of Circulating T Cells | Phase 1: Balstilimab Dose 2 | Cycle 2 Day 1 | 61.6 | Standard Deviation 1.70 | percent occupancy |
| Phase 1: Receptor Occupancy of Circulating T Cells | Phase 1: Balstilimab Dose 4 | Cycle 2 Day 1 | 72.1 | Standard Deviation 8.29 | percent occupancy |
| Phase 1: Maximum Observed Concentration (Cmax) of Balstilimab | Phase 1: Balstilimab Dose 1 | Cycle 1 Day 1 | 18.1 | Geometric Coefficient of Variation 34.3 | ug/mL |
| Phase 1: Maximum Observed Concentration (Cmax) of Balstilimab | Phase 1: Balstilimab Dose 2 | Cycle 1 Day 1 | 71.9 | Geometric Coefficient of Variation 19.5 | ug/mL |
| Phase 1: Maximum Observed Concentration (Cmax) of Balstilimab | Phase 1: Balstilimab Dose 3 | Cycle 1 Day 1 | 153 | Geometric Coefficient of Variation 23.7 | ug/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03104699/results